Company ProfilePremium

Aminologics Co., Ltd.

Company Profile Analysis

Ticker: 074430.KQ주

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aminologics Co., Ltd. - Company showcase

Year Founded & Workforce

1997

40 Employees

Aminologics Co., Ltd. logo

Aminologics Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aminologics Co., Ltd. Overview

Key identifiers

ItemDetailSource
Legal nameAminologics Co., Ltd. ((주)아미노로직스)[S1]
Former nameA-Logics Co., Ltd. ((주)에이로직스), renamed Aminologics in September 2009[S1]
Founding / incorporation date3 September 1997[S1]
Incorporation jurisdictionRepublic of Korea[S1]
Headquarters3F Samoh Building, 151 Yeoksam-ro, Gangnam-gu, Seoul, Korea (Tel +82-2-761-4570)[S1], [S5]
R&D centre55 Osongsaengmyeong 5-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do (established 8 January 2010)[S3]
Exchange / tickerKOSDAQ (Korea Exchange): 074430[S15]
KOSDAQ registrationJune 2004[S1], [S15]
ISIN / CUSIP——
Fiscal year end31 December[S13]
Shares outstanding88.14 million (30 June 2026); 87.83 million from Q4 2015 through Q1 2026[S13]
Employees40 (aggregator figure; reference date not stated)[S15]
Employee trend (3-year)——
Auditor——
Representative directors (co-CEOs)Oh Jang-seok and Oh Seong-seok[S1], [S2]
Largest shareholderSamoh Pharm Co., Ltd. (삼오제약), 31.81% (end-2025)[S6]
Share priceKRW 977 (close, 15 October 2026)[S13]
Market capitalisation≈ KRW 86.1 bn (KRW 977 × 88.14 m shares; analyst calculation). Aggregators quoted KRW 88.9–89.5 bn on 14–15 October 2026 using slightly different share counts/prices[S13], [S17]
52-week rangeKRW 855 – KRW 1,940[S17]
Business scope (as registered)Manufacture of amino acids, amino acid derivatives and pharmaceutical intermediates; wholesale of active pharmaceutical ingredients[S1]

Aminologics is a small Korean specialty-chemicals company that develops and sells non-natural (unnatural) and D-configured amino acids, protected amino acids (Fmoc, Boc, Cbz) and peptide-side-chain building blocks, built on a proprietary chiral-resolution platform it calls ARCA. A second, shrinking segment distributes six active pharmaceutical ingredients in Korea under domestic rights acquired from its parent, Samoh Pharm, in 2015. The company is asset-light: it owns no manufacturing plant and relies on contract manufacturing, principally Samoh's cGMP plant in Osong. Its strategic relevance has risen with global demand for GLP-1 peptide drugs, for which its catalogue now features semaglutide-, liraglutide- and tirzepatide-type side-chain intermediates. Its economic reality, however, is that of a captive technology-and-sales arm of the Samoh group: roughly 77% of 2025 revenue was booked through Samoh, which also controls the board and holds about 32% of the equity.


What the company does

Aminologics operates two reportable business lines: an Amino Acid business and an API (원료의약품, active pharmaceutical ingredient) business [S6], [S7], [S20].

Amino Acid business. After setting up a research institute in the second half of 2009, the company began researching, manufacturing and selling amino acids and amine-type compounds [S9]. It has since developed several dozen unnatural amino acids and D-amino acid derivatives, and has commercialised application materials such as protected amino acids, amino esters and oligopeptides [S9]. Named examples in its own descriptions include D-Serine, D-Phenylalanine and beta-Phenylalanine [S20]. The website catalogue lists 142 products across six families: amino acids and derivatives; Fmoc-protected amino acids; Boc-protected amino acids; Cbz-protected amino acids; Fmoc α-amino acids; and lipids and linkers [S4]. These materials are building blocks for peptide drugs, small-molecule APIs, agrochemicals and other fine chemicals [S14], [S8].

API business. In 2015 Aminologics acquired from its largest shareholder, Samoh Pharm, the domestic Korean business rights to six APIs for KRW 19.0 bn [S6]. It supplies these APIs — used in products for stroke, eye disease, dermatitis and cosmetics — to multiple Korean finished-dosage manufacturers [S20]. The specific API molecules are not named in the sources reviewed.

Business model and revenue model

DimensionCharacterisationBasis
Revenue type~100% product sales (amino acid materials and traded APIs); no disclosed service, subscription or licensing revenue[S6], [S13]
Manufacturing modelOutsourced: production through external contract manufacturers, starting in January 2017 with Samoh Pharm's Osong plant; the company has no production facility of its own[S9], [S7]
Sales channels(1) indirect export via trading/distribution specialists including Samoh Pharm; (2) direct export to end buyers[S6]
Customer typesGlobal pharmaceutical companies and peptide manufacturers (amino acids); Korean finished-dose pharma companies (APIs)[S8], [S20]
End-marketsPeptide therapeutics (including GLP-1 class), small-molecule pharma intermediates, agrochemicals, sweeteners, cosmetics, research[S8], [S14], [S5]
Value-chain positionUpstream "raw material of the raw material": chiral building blocks sold to API/peptide manufacturers[S11]

Company's own description

The company describes itself (paraphrased from its CEO message) as having pursued, since 2009, the development of diverse biomaterials through chiral separation of amino acids based on its ARCA source technology, with the aim of commercialising amino acid technologies that drive both pharmaceutical and fine-chemical industries; it frames its unnatural-amino-acid work as a "first mover" role [S2]. A third-party English summary of its filings describes it as a specialty manufacturer of amino acids and derivatives whose core competency is the proprietary ARCA chiral-resolution platform, an enzymatic process enabling cost-effective production of high-purity chiral amino acids for pharmaceutical, fine-chemical, agrochemical and life-science uses [S14].

Independent characterisation

Aminologics is best understood as a captive specialty-materials sales and development company within the Samoh Pharm group, not as a vertically integrated manufacturer. Three facts define it:

  1. Technology without plant. The value proposition rests on process know-how (ARCA and downstream protection chemistry) and a catalogue of 140-plus SKUs, while physical production sits with Samoh's Osong cGMP plant and other CMOs [S7], [S4].

  2. Extreme customer concentration through the parent. Sales to Samoh were KRW 17.0 bn in FY2025, or 77.27% of revenue; about 96% of the Amino Acid segment's FY2025 sales of KRW 17.7 bn went to Samoh, which acts as a trading channel to end buyers [S6]. Revenue quality therefore depends on the opacity of Samoh's onward sales.

  3. Mix shift to peptide building blocks. The Amino Acid segment rose from 37.4% of revenue in 2021 to 80% in FY2025 (KRW 17.7 bn of 22.0 bn) and 87% in Q2 2026 [S9], [S6], [S12]. The featured catalogue items — e.g., Fmoc-Lys(AEEAc-AEEAc-(γ-Glu-OtBu)-17-t-butoxycarboxyheptadecanoyl)-OH (CAS 1662688-20-1), tBuO-Ste-Glu(AEEA-AEEA-OSu)-OtBu (CAS 1118767-15-9), Fmoc-Lys(Pal-Glu-OtBu)-OH (CAS 1491158-62-3) and 20-(tert-butoxy)-20-oxoicosanoic acid (CAS 683239-16-9) [S4] — are, on structural analysis by this analyst, side-chain intermediates of the semaglutide, liraglutide and tirzepatide type. The company does not publicly name the drugs its materials serve; this mapping is the analyst's inference from chemical structure.

Strategy

Stated strategy (themes paraphrased from company and press sources)

ThemeCompany statement (paraphrased)Source
First-mover in unnatural amino acidsPositions ARCA-based unnatural amino acids as foundational technology that will generate future earnings and benefit society[S2]
Expand into higher-value derivativesLong-term goal (2012) to secure as many unnatural amino acid technologies as possible and expand into higher-value amino acid derivatives[S10]
Peptide raw-material specialistSeeks to be a specialist developer/seller of amino acid derivatives for fast-growing peptide drugs; markets at CPhI Japan and Europe[S8]
Cost competitivenessOptimising production processes and cutting overheads to improve manufacturing cost[S8]
Capacity in R&D talentPre-emptively expanding research staff to develop and supply high-quality products on time[S8]
ESG supply-chain credentialsPursuing EcoVadis assessment and ISO certifications (anti-bribery, environment, health & safety) because global pharma customers require them[S8]
Customer-pull product developmentDescribes a co-growth model in which global customers, having recognised its quality, request new product development[S20]
Reducing parent dependenceOfficial said the company is considering, long term, how to reduce reliance on Samoh[S6]

Initiatives announced in the last 24 months

InitiativeDateDetailSource
KRW 20 bn 4th private CBJun 2025Proceeds for operating and R&D funds; Samoh took 25% (KRW 5 bn)[S6]
Normalisation of legacy issuesStated Apr 2026Company said the long process of normalising a previously acquired company was concluded with 2025, and past difficulties had largely been resolved[S6]
GLP-1 side-chain portfolioVisible on website (date of addition not disclosed)Featured products are acylated-peptide side chains and linkers[S4]

No transformation programme, cost programme with quantified targets, new business launch, platform investment or medium-term financial targets were identified. Management guidance: none publicly issued.

Products & Services

Platform technology: ARCA

ItemDetailSource
NameARCA (described in a third-party filings summary as "Alanine Racemase Chiral" technology)[S14]
NatureEnzymatic chiral-resolution/conversion platform[S14]
Claimed advantagesOperates at room temperature and atmospheric pressure; a single technology can produce many unnatural amino acids in optically pure form, avoiding the narrow substrate scope of conventional enzymatic routes and the harsh conditions or resolving-agent recovery of chemical routes[S3]
Sub-systems shown on website"Shuttle System" and "Conversion System"[S5]
OriginDomestically developed source technology; licensed from AminoLux (Oct 2009)[S3], [S1]
Positioning (2012)Management characterised it as the world's first source technology able to mass-produce diverse amino acids with one catalyst, opening the mid/low-price amino acid market as well as the high-price segment[S10]

Catalogue structure (Amino Acid segment)

Product familyDescriptionRepresentative productsTarget customerSource
Amino Acids & DerivativesUnprotected D-, L- and non-proteinogenic amino acidsD-Phenylalanine; D-Alanine; D-allo-Isoleucine; D-Serine; S-beta-Phenylalanine; 3-(2-Naphthyl)-D-alanine; 3-(2-Naphthyl)-L-alanine; 3-(3-Pyridyl)-D-alanine; 3-(3-Pyridyl)-L-alanine; 4-Chloro-D-phenylalanine; 4-Chloro-L-phenylalanineAPI and peptide manufacturers; agrochemical and fine-chemical makers[S18], [S20]
Boc-protected Amino Acidstert-Butoxycarbonyl-protected building blocks for peptide synthesisBoc-D-Phenylalanine; Boc-D-Ser-OH; Boc-D-4-benzoylphenylalanine; Boc-AEEA-OH DCHA (CAS 560088-79-1)Peptide synthesis (Boc chemistry)[S18], [S4]
Fmoc-protected Amino AcidsFluorenylmethoxycarbonyl-protected building blocks for solid-phase peptide synthesisFmoc-Lys(Pal-Glu-OtBu)-OH (CAS 1491158-62-3); Fmoc-Lys(AEEAc-AEEAc-(γ-Glu-OtBu)-17-t-butoxycarboxyheptadecanoyl)-OH (CAS 1662688-20-1)Peptide API manufacturers (SPPS)[S4]
CBZ-protected Amino AcidsBenzyloxycarbonyl-protected amino acidsIndividual SKUs not itemised in sources reviewedPeptide and small-molecule synthesis[S4]
Fmoc α-Amino Acidsα-substituted Fmoc amino acidsIndividual SKUs not itemised in sources reviewedPeptide drug developers[S4]
Lipids & LinkersFatty-diacid, OEG linker and activated side-chain fragments used in half-life-extended peptidesPal-Glu(OSu)-OH (CAS 294855-91-7); 20-(tert-Butoxy)-20-oxoicosanoic acid (CAS 683239-16-9); tBuO-Ste-Glu(AEEA-AEEA-OSu)-OtBu (CAS 1118767-15-9); tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu (CAS 1118767-16-0); Octadecanedioic acid mono-tert-butyl ester (CAS 843666-40-0); H-AEEA-AEEA-OH (CAS 1143516-05-5)GLP-1 and other acylated-peptide API manufacturers[S4]

All nine "featured" products on the website are listed with optical purity above 99.5% [S4]. The catalogue totals 142 products, and the company states it develops new products on customer request [S4]. Pricing is not publicly disclosed; launch years per SKU are not disclosed.

Flagship offerings — analyst mapping to end products

Featured product (CAS)Analyst's structural interpretationConfidence
Fmoc-Lys(AEEAc-AEEAc-(γ-Glu-OtBu)-17-t-butoxycarboxyheptadecanoyl)-OH (1662688-20-1)Pre-assembled lysine-plus-side-chain building block of the semaglutide type (C18 diacid–γGlu–OEG–OEG)Analyst inference; company does not name drugs
tBuO-Ste-Glu(AEEA-AEEA-OSu)-OtBu (1118767-15-9) and -OH form (1118767-16-0)Activated semaglutide-type side chain for late-stage acylationAnalyst inference
Octadecanedioic acid mono-tert-butyl ester (843666-40-0)C18 fatty-diacid starting material for semaglutide-type side chainsAnalyst inference
Fmoc-Lys(Pal-Glu-OtBu)-OH (1491158-62-3); Pal-Glu(OSu)-OH (294855-91-7)Palmitoyl-γGlu side-chain building blocks of the liraglutide typeAnalyst inference
20-(tert-Butoxy)-20-oxoicosanoic acid (683239-16-9)C20 fatty-diacid fragment of the tirzepatide typeAnalyst inference

This mapping matters because it places Aminologics in the GLP-1 supply chain, which the Korean press cited as the driver of the January 2026 share-price spike [S7].

API segment portfolio

ItemDetailSource
Number of APIsSix[S6], [S20]
Therapeutic areasStroke, eye disease, dermatitis, cosmetics[S20]
Rights scopeDomestic (Korea) business rights[S6]
Acquired from / priceSamoh Pharm, 2015, KRW 19.0 bn[S6]
CustomersMultiple Korean finished-pharma companies[S20]
Carrying value of rights (customer relationships, other intangibles)KRW 1.96 bn at end-2025 after successive impairments[S6]
Named molecules——

Financial Narrative

Income statement: notes and sources

Sources: Revenue, operating income and net income FY2021–FY2025 from DART-compiling aggregators [S11], [S12]; FY2025 cost of sales, gross profit, SG&A, EBITDA, pre-tax income and EPS from [S13]. FY2025 revenue is reported as KRW 22.0 bn (+30.9% YoY in IB Tomato's DART-based account; +31.1% in aggregator data — the small difference reflects rounding of the FY2024 base) [S6], [S12].

Margins and growth

Sources: growth rates [S11]; margins calculated by the analyst from [S11], [S12], [S13].

Revenue CAGR: FY2021–FY2025 ≈ -0.9% p.a.; FY2016–FY2025 ≈ +3.3% p.a. (KRW 16.4 bn to KRW 22.0 bn) [S11], analyst calculation. The company's revenue base has, in effect, oscillated between KRW 16 bn and KRW 27 bn for a decade.

Ten-year context: notes and sources

Source: [S11].

Trailing-twelve-month and interim data: notes and sources

Source: [S13] (aggregator annualised series).

Source: [S11]. H1 2026 revenue was therefore ≈ KRW 13.6 bn and operating income ≈ KRW 2.6 bn (analyst sum).

FY2025 cost and below-the-line detail

The derivative losses and interest expense emerged in FY2025 alongside the KRW 20 bn convertible bond.

Balance sheet: notes and sources

Sources: [S13] for assets, current assets, cash and short-term instruments; [S11] for liabilities-to-equity ratio. Equity and liabilities derived by the analyst as Total assets ÷ (1 + ratio); rounding of the ratio introduces error of roughly ±KRW 0.5 bn. At 30 June 2026 total assets were KRW 89.71 bn and current assets KRW 70.04 bn [S13].

Cash flow: notes and sources

Source: [S11]. Structurally, capex should be minimal because the company owns no plant [S7]; the FY2025 increase in cash plus short-term instruments (≈ KRW 17.6 bn) is largely explained by the KRW 20 bn CB issued in June 2025 [S6], [S13].

Ratios

An aggregator reports TTM ROE of 5.41% at 30 June 2026 [S13].

Commentary on trends, inflections and drivers

FY2021–FY2022: peak on an API-heavy mix. FY2021 revenue rose 29.5% and FY2022 a further 19.6% to a record KRW 27.3 bn, with operating margin peaking at 25.6% [S11]. Q1 2022 showed both segments contributing roughly equally (API KRW 3.9 bn, amino acids KRW 4.2 bn) [S9]. The KRW 7.3 bn net loss in FY2022 despite KRW 7.0 bn of operating profit [S12] signals a large non-operating charge; its nature is not documented in the sources reviewed and should be checked against the FY2022 business report (an impairment of the API business rights is a plausible candidate, as is a loss on financial assets).

FY2023–FY2024: API collapse. Revenue fell 23.6% and then 19.6% [S11]. Since amino acid sales exceeded KRW 15 bn in 2023 and were KRW 11.5 bn in 2024 [S8], [S6], while API sales were only KRW 5.3 bn in 2024 [S6], the API segment appears to have contracted from roughly KRW 14 bn (FY2021) to KRW 5 bn. Amino acid sales also dipped in 2024, coinciding with Samoh's share of revenue falling to 66.67% [S6]. Fixed SG&A (≈ KRW 6 bn) on a smaller base drove the FY2024 operating loss of KRW 2.2 bn.

FY2025–H1 2026: amino-acid-led recovery. Amino acid revenue jumped 54% to KRW 17.7 bn, lifting group revenue 31% and operating margin to 16.3% [S6]. Gross margin reached 44.8% for FY2025 and ≈47.4% on a TTM basis to June 2026 [S13], analyst calculation. Q2 2026 was the strongest quarter since the 2022 peak (revenue KRW 8.2 bn, OP KRW 2.0 bn) [S11]. TTM operating margin to June 2026 was ≈20.9% [S13], analyst calculation.

Balance sheet transformed by the CB. Liabilities-to-equity moved from 10% to 50% in FY2025 purely through the KRW 20 bn CB [S11], [S6]; with cash and short-term instruments of ≈KRW 53 bn, the company remains net cash. The cost is (a) CB-related finance costs and derivative volatility in the P&L, and (b) potential dilution of roughly 20.9 million shares (≈23.8% of the pre-conversion share base) at the KRW 957 conversion price (analyst calculation from [S7]).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / servicesSource

Amino Acid (아미노산)

Development and sale of unnatural amino acids, D-amino acid derivatives and application materials

Protected amino acids (Fmoc/Boc/Cbz), amino esters, oligopeptides, lipid and linker side-chain building blocks

[S9], [S4], [S20]

API (원료의약품)

Distribution of six APIs under domestic Korean rights acquired from Samoh Pharm (2015)

APIs used in stroke, ophthalmic, dermatitis and cosmetic products

[S6], [S20]

Amino Acid

Predominantly Korea (via Samoh) plus direct export

Global pharma/peptide buyers; specific regions not disclosed

[S6], [S8]

API

Korea

Korea

[S6], [S20]

Segment revenue (KRW Bn)

Segment revenue (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Amino Acid revenue (KRW Bn)

8.5——11.517.7

API revenue (KRW Bn)

14.3——5.34.3

Total revenue (KRW Bn)

22.827.320.916.822.0

Revenue by Segment (%) and Segment Margins & Growth (%)

Segment metricFY2021FY2024FY2025

Amino Acid share of revenue (%)

37.468.580.5

API share of revenue (%)

62.631.519.5

Amino Acid YoY growth (%)

——53.9

API YoY growth (%)

——-18.9

Sales to Samoh Pharm

Sales to Samoh PharmFY2023FY2024FY2025

Sales to Samoh Pharm (KRW Bn)

15.911.217.0

Share of total revenue (%)

76.0866.6777.27

Income statement (KRW Bn)

Income statement (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

22.827.320.916.822.0

Cost of sales (KRW Bn)

————12.16

Gross profit (KRW Bn)

————9.86

SG&A (KRW Bn)

————6.26

Operating income (KRW Bn)

4.17.01.5-2.23.6

EBITDA (KRW Bn)

————3.70

Pre-tax income (KRW Bn)

————3.51

Net income (KRW Bn)

5.4-7.32.4-1.63.5

EPS basic (KRW)

————40.1

Margins and growth

Margins and growthFY2021FY2022FY2023FY2024FY2025

Revenue growth YoY (%)

29.519.6-23.6-19.631.1

Gross margin (%)

————44.8

Operating margin (%)

18.025.67.2-13.116.3

EBITDA margin (%)

————16.8

Net margin (%)

23.7-26.711.5-9.516.0

Income Statement

Ten-year history (KRW Bn)FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

16.416.818.419.017.722.827.320.916.822.0

Operating income (KRW Bn)

0.81.14.2-0.82.54.17.01.5-2.23.6

Income Statement (TTM Jun-2025–TTM Jun-2026)

TTM metric (KRW Bn)TTM Jun-2025TTM Sep-2025FY2025TTM Mar-2026TTM Jun-2026

Revenue (KRW Bn)

15.9019.5122.0222.6726.15

Gross profit (KRW Bn)

3.957.639.8610.2312.39

Operating income (KRW Bn)

-1.791.733.593.715.47

EBITDA (KRW Bn)

-1.162.353.702.925.61

Net income (KRW Bn)

-0.941.953.522.253.15

Income Statement and Margin Analysis (%)

Quarterly results (KRW Bn)Q1 2026Q2 2026

Revenue (KRW Bn)

5.48.2

Revenue YoY (%)

13.973.1

Operating income (KRW Bn)

0.62.0

Net income (KRW Bn)

1.11.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

FY2025 Line Item Details

FY2025 line itemKRW Bn

Raw materials within cost of sales

3.03

Salaries within SG&A

3.47

Commissions paid

0.72

R&D expense recognised in SG&A

0.14

Depreciation in SG&A

0.47

Finance income

3.62

of which interest income

1.28

of which gain on disposal of financial assets

1.51

Finance costs

2.73

of which interest expense

0.98

of which derivative losses

1.51

Asset impairment (non-operating)

1.05

Income tax expense

0.00

Balance Sheet and Margin Analysis (%)

Balance sheet (KRW Bn)FY2022FY2023FY2024FY2025

Total assets (KRW Bn)

55.5857.6656.7884.17

Current assets (KRW Bn)

43.5645.2446.5178.61

Cash and cash equivalents (KRW Bn)

12.7311.9918.8826.45

Short-term financial instruments (KRW Bn)

16.5016.5016.5026.50

Liabilities-to-equity ratio (%)

861050

Total equity, derived (KRW Bn)

51.4654.4051.6256.11

Total liabilities, derived (KRW Bn)

4.123.265.1628.06

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Additional Balance-sheet Items Details

Additional balance-sheet itemsDetailSource

Net cash, FY2025 (analyst estimate)

≈ KRW 33 bn (cash 26.45 + short-term instruments 26.50 − CB face 20.0)

[S13], [S6]

Goodwill

None identified

—

Intangibles — API business rights

KRW 1.96 bn (end-2025)

[S6]

Cash flow (KRW Bn)

Cash flow (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Net change in cash (KRW Bn)

0.14.2-0.66.87.4

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025Basis

ROE (%)

-3.06.5

Net income ÷ average derived equity; analyst calculation

ROA (%)

-2.85.0

Net income ÷ average total assets; analyst calculation

Liabilities/equity (%)

1050

[S11]

Net debt/EBITDA (x)

Net cash

Net cash

Analyst calculation

Interest coverage, OP ÷ interest expense (x)

—3.7

[S13]; largely non-cash CB accretion

Asset turnover (x)

0.290.31

Revenue ÷ average total assets; analyst calculation

Share Price History

DatePrice (KRW)Context

9 Jun 2022

2,745 (intraday)

Rally on unnatural amino acid growth

30 Jun 2025

1,137

Quarter-end

30 Sep 2025

995

Quarter-end

26 Dec 2025

915

Pre-rally

31 Dec 2025

1,194

Year-end

6 Jan 2026

1,940 (intraday high)

52-week high

31 Mar 2026

1,364

Quarter-end

30 Jun 2026

1,136

Quarter-end

15 Oct 2026

977

Latest close

Share Price & Returns

PeriodReturnBasis

Year-to-date 2026

-18.2%

KRW 1,194 → KRW 977; analyst calculation [S13]

Since 30 Sep 2025 (~1 year)

-1.8%

KRW 995 → KRW 977; analyst calculation [S13]

From 6 Jan 2026 intraday peak

-49.6%

KRW 1,940 → KRW 977; analyst calculation [S7], [S13]

From Jun 2022 level

≈-64%

KRW 2,745 → KRW 977; analyst calculation [S9]

Valuation Snapshot

MultipleValueBasis

Market capitalisation

≈KRW 86.1 bn

88.14 m shares [S13]

P/E (TTM to Jun-2026)

≈27.3x

Net income KRW 3.15 bn [S13]; analyst calc.

P/E (FY2025)

≈24.5x

Net income KRW 3.52 bn [S12]; analyst calc.

P/B

≈1.5x

Aggregator PBR 1.53 [S13]

Enterprise value (approx.)

≈KRW 53 bn

Mkt cap + CB face KRW 20 bn − cash and short-term instruments KRW 52.95 bn (end-2025); analyst calc.

EV/Sales (TTM)

≈2.0x

Analyst calc.

EV/EBITDA (TTM)

≈9.5x

EBITDA KRW 5.61 bn [S13]; analyst calc.

Aggregator P/E range quoted

28.3x–34.2x

Varying dates/prices [S13], [S12]

Valuation Multiple History Details

Valuation multiple historyFY2025

Year-end P/E (x)

29.8

Capital Markets

ItemDetail

Dividend policy

Not publicly stated

Historical dividends

An aggregator lists past annual dividends of KRW 30 and KRW 20 per share paid in April of earlier years

Recent dividends

Aggregators show no dividend yield for the current period

Buyback authorisations

None identified; aggregator shows no treasury-share ratio

Moody's / S&P / Fitch ratings

None (unrated issuer)

Domestic credit ratings

None identified

Debt instrument

4th private CB, KRW 20 bn face, issued Jun 2025; Samoh holds KRW 5 bn

Conversion price

KRW 957

Conversion start

30 Jun 2026

Analyst Conclusions

Guidance and consensus

Management provides no financial guidance, and there is no consensus [S17]. The only forward-looking management comments in the public domain are that the normalisation of legacy problems concluded with 2025 and that the company is considering how to reduce dependence on Samoh over the long term [S6].

Bull case

  1. Earnings inflection is real and accelerating. TTM operating income reached KRW 5.47 bn to June 2026, up from a KRW 1.79 bn TTM loss a year earlier, on TTM revenue of KRW 26.15 bn — the highest level since FY2022 [S13]. Q2 2026 revenue grew 73.1% [S11].

  2. Exposure to the strongest pharma growth vector. The featured catalogue consists of GLP-1-type side chains [S4]; the largest peptide CDMO guides 35–45% growth for 2026 [S21]. A small supplier can grow quickly if a single programme ramps.

  3. Downside cushioned by net cash. With ≈KRW 53 bn of cash and short-term instruments against a KRW 20 bn CB (end-2025) [S13], [S6], the implied EV of ≈KRW 53 bn is about 9.5x TTM EBITDA — undemanding if growth persists.

Bear case

  1. Revenue is effectively one related-party customer. About 96% of amino acid sales go to Samoh [S6]; the history of the 2015 API-rights purchase (KRW 19.0 bn, now KRW 1.96 bn) [S6] shows that related-party dealings have destroyed minority value before.

  2. Dilution overhang caps upside. The KRW 20 bn CB converts at KRW 957 into ≈20.9 m shares, with the share price now only ≈2% above the conversion price [S7], [S13]; holders can convert on any rally.

  3. Structural competitive disadvantage. No owned plant, minimal visible R&D spend (KRW 0.14 bn SG&A line, FY2025) [S13], and better-capitalised entrants — Daesang/AMINO GmbH at ~105% utilisation and KRW 26.5 bn quarterly revenue [S23] — make sustained share gains uncertain.

Catalysts and monitorables (next 12 months)

MonitorableWhy it mattersTiming
Q3 2026 reportTests whether Q2's KRW 8.2 bn revenue is sustainable≈14 Nov 2026
CB conversion filings and large-holding reportsSize and pace of dilution; Samoh's post-conversion stakeOngoing
Samoh share of revenue in FY2026 business reportEvidence of direct-export diversificationMar 2027
Further API-rights impairmentResidual KRW 1.96 bnFY2026 audit
Korean GLP-1 manufacturing announcementsPotential local demand for side chainsEvent-driven
EcoVadis/ISO completionCustomer-qualification credentialsNot scheduled
Disclosure of any long-term supply agreementWould de-risk revenue visibilityEvent-driven

Analyst verdict

Aminologics is a genuinely interesting technology asset trapped inside an unattractive corporate structure. On the technology side, the evidence is favourable: a domestically developed chiral platform that the company says produces many optically pure unnatural amino acids under mild conditions [S3]; a catalogue that has moved decisively toward the highest-value niche in peptide chemistry — GLP-1-type acylated side chains [S4]; and a financial recovery that, on TTM numbers to June 2026, shows revenue of KRW 26.2 bn and an operating margin near 21% [S13]. A net cash balance sheet [S13], [S6] means the business is not at financial risk.

On the structural side, the evidence is equally clear and less favourable. Roughly 77% of group revenue and about 96% of amino acid revenue run through the controlling shareholder [S6], which also manufactures the products [S7] and fills the board with family members [S7]. Minority shareholders therefore cannot observe end-customer demand, pricing or contract terms, and must trust a related-party channel whose last major asset sale to the company (the 2015 API rights) has been written down by about 90% [S6]. Layered on top is a live KRW 20 bn convertible overhang struck at KRW 957 [S7] — almost exactly today's KRW 977 share price [S13].

The January 2026 episode, in which the shares nearly doubled on second-hand GLP-1 speculation and then gave it all back [S7], [S13], illustrates how this stock trades: on themes rather than on disclosed fundamentals. Our synthesis is that the stock is fairly valued on present information at ≈9.5x TTM EBITDA (EV basis), with asymmetric event risk in both directions. A re-rating would require either disclosure of named end-customers or long-term contracts, or a visible decline in related-party revenue share. Absent those, the CB overhang and governance discount are likely to cap the shares near the conversion price.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRole at AminologicsOther roles / backgroundTenureSource

Oh Jang-seok (오장석)

Co-Representative Director (co-CEO); board member

Chairman and co-CEO of Samoh Pharm

Start date not disclosed in sources (Samoh control since 2014)

[S1], [S2], [S7]

Oh Seong-seok (오성석)

Co-Representative Director (co-CEO); board member

Vice Chairman and co-CEO of Samoh Pharm

—

[S1], [S2], [S7]

Oh Ju-hyung (오주형)

Director

President of Samoh Pharm; eldest son of Oh Jang-seok

—

[S7]

Oh Seung-ye (오승예)

Director

President of Samoh Pharm; eldest daughter of Oh Seong-seok

—

[S7]

Byun Il-seok (변일석)

Head of R&D centre

——

[S3]

Kwan-Woong Jo (age 51)

Listed as director

——

[S16]

Sung-Goo Park (age 63)

Listed as director

——

[S16]

Yeon-Jin Kim (age 59)

Listed as director

——

[S16]

Sung-Cheol Park (age 64)

Listed as director

——

[S16]

In-Ho Choi (age 68)

Listed as director

——

[S16]

“—” = not publicly disclosed.

Major Shareholders

HolderStakeReference dateSource

Samoh Pharm Co., Ltd.

31.81%

End-2025

[S6]

Samoh Pharm (earlier reference)

~31%

30 Sep 2025

[S7]

Samoh group affiliate (reported as "심오파마켐", likely Samoh Pharmachem)

0.67%

30 Sep 2025

[S7]

Oh Jang-seok

0.32%

30 Sep 2025

[S7]

Oh Seong-seok

0.32%

30 Sep 2025

[S7]

Largest shareholder and related parties (sum)

≈33.1%

Analyst sum

[S6], [S7]

Potential: Samoh conversion of KRW 5 bn CB

≈5.22 m shares

If fully converted at KRW 957

[S7]

Competitive Landscape

Key Competitors

CompetitorCountrySegment overlapRelative positioning vs AminologicsSource / basis

Bachem Holding AG

Switzerland

Protected amino acids, peptide building blocks, peptide APIs (also a potential customer)

Global leader, vastly larger and integrated

[S21]

AMINO GmbH (Daesang)

Germany/Korea

Pharma- and infusion-grade amino acids

Plant-owning, high utilisation, now backed by Daesang

[S23]

Daebong LS

Korea

Pharma amino acids (NAC, carbocisteine) and peptides; GLP-1 ambitions

Larger, diversified, own GMP plant

[S22], [S28]

Ajinomoto

Japan

Pharma amino acids, peptide CDMO

Global integrated leader

—

Kyowa Hakko Bio (Kirin)

Japan

Pharma and nutrition amino acids

Fermentation-scale leader

—

Evonik (Rexim)

Germany/France

Pharma-grade amino acids and derivatives

Major global pharma amino acid supplier

—

Merck KGaA (Novabiochem/MilliporeSigma)

Germany

Fmoc/Boc building blocks

Dominant catalogue supplier to research and development markets

—

Iris Biotech

Germany

Unnatural and protected amino acids, linkers

Specialist catalogue house

—

Watanabe Chemical Industries

Japan

Protected amino acids

Specialist Japanese supplier

—

Senn Chemicals

Switzerland

Amino acid derivatives

Specialist European supplier

—

Chinese protected-amino-acid and GLP-1 side-chain makers (e.g., Suzhou Highfine Biotech, GL Biochem)

China

Fmoc amino acids, GLP-1 side chains

Price-aggressive, large-scale; principal pricing threat

—

Peer Comparison FY2025

MetricAminologics (FY2025)Bachem (FY2025)Daebong LS (FY2025)AMINO GmbH (Q2 2026 only)

Revenue

KRW 22.0 bn

CHF 695.1 m

KRW 102.1 bn

KRW 26.5 bn (one quarter)

Revenue growth YoY

+31.1%

+14.8% (+19.2% LC)

+8.6%—

Operating/EBIT margin

16.3% (OP)

24.1% (EBIT)

7.1% (OP, analyst calc.)

—

EBITDA margin

16.8%30.9%——

R&D intensity

≥0.6% (SG&A line only)

———

Own manufacturing

No

Yes

Yes

Yes

“—” = not publicly disclosed.

Recent Developments

Company events

DateEventSignificanceSource
15 May 2025Q1 2025 quarterly report filedStart of recovery year[S11]
Jun 2025KRW 20 bn 4th private CB issued; Samoh subscribed KRW 5 bn; conversion price KRW 957Funded liquidity; created ~20.9 m-share overhang[S6], [S7]
14 Aug 2025H1 2025 report filedTTM revenue still only KRW 15.9 bn at mid-year[S11], [S13]
14 Nov 2025Q3 2025 report filed: 9M revenue KRW 15.5 bn (amino acids 77%)Confirmed amino acid-led recovery[S7], [S11]
26 Dec 2025Share price closes at KRW 915Pre-rally base[S7]
30 Dec 2025Share price jumps to KRW 1,194Start of GLP-1-themed rally[S7]
2 Jan 2026Shares rise 20% to KRW 1,438Momentum on GLP-1 theme[S7]
5 Jan 2026KRX designates investment warning advance notice; intraday 52-week high KRW 1,825; close KRW 1,681Regulatory cooling measure after ~84% five-session gain[S7]
6 Jan 2026Intraday high KRW 1,940 (52-week high); close KRW 1,682; market cap ≈KRW 147.7 bnPeak valuation; Samoh's stake valued ≈KRW 45.8 bn[S7]
12 Mar 2026Notice of 29th AGM with e-voting via Samsung SecuritiesGovernance[S5]
23 Mar 2026FY2025 business report filedRevenue KRW 22.0 bn, OP KRW 3.6 bn, NI KRW 3.5 bn[S14], [S6]
31 Mar 202629th AGM results; FY2025 settlement noticeGovernance[S14], [S5]
29 Apr 2026IB Tomato analysis highlights record dependence on Samoh and API-rights impairmentsRaised governance/quality-of-earnings concerns[S6]
15 May 2026Q1 2026 report: revenue KRW 5.4 bn (+13.9%), OP KRW 0.6 bnSlow start to 2026[S11]
30 Jun 20264th CB conversion window opensDilution overhang becomes live[S7]
10 Jul 2026Large shareholding status report filedOwnership change[S14]
13 Jul 2026Large shareholding status report and officer/major-shareholder ownership report filedOwnership change[S14]
14 Aug 2026H1 2026 report: Q2 revenue KRW 8.2 bn (+73.1%), OP KRW 2.0 bn; amino acids 87% of Q2 revenueBest quarter since 2022[S11], [S12]
15 Oct 2026Share closes at KRW 977, near the bottom of its 52-week rangeRally fully reversed[S13], [S17]

Sector events relevant to Aminologics

DateEventRelevanceSource
Dec 2025 – Mar 2026Daesang announced (Dec 2025) and completed (Mar 2026) acquisition of 100% of German specialty amino acid producer AMINO GmbH for ≈KRW 50.2 bnA large Korean food-chemicals group entering high-purity/pharma amino acids — a new domestic competitor with plant capacity[S23]
12 Mar 2026Bachem FY2025: sales CHF 695.1 m (+14.8%); 2026 guidance 35–45% growth in local currencyConfirms strong peptide/GLP-1 demand for upstream materials[S21]
Jul 2026Daebong LS selected for a global GMP support programme (≈KRW 0.4 bn) to prepare pharma amino acids for US FDA, partnering with CJ CheilJedang on four essential amino acidsAnother Korean listed company moving toward pharma-grade amino acids[S28]
Aug 2026AMINO GmbH reported ~105% plant utilisation with Q2 revenue of KRW 26.5 bn within DaesangScale gap: one competitor's quarterly revenue exceeds Aminologics' annual revenue[S23]

Company Snapshot

$15.5M

Revenue

40

Employees

1997

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Proprietary chiral platform: ARCA produces diverse optically pure unnatural amino acids at ambient temperature/pressure [S3]
  • High-value product mix: Featured products are GLP-1-type side chains with >99.5% optical purity [S4]
  • Strong recovery momentum: Amino acid revenue +54% in FY2025 to KRW 17.7 bn [S6]; Q2 2026 revenue +73.1% [S11]
  • Margin leverage: FY2025 gross margin 44.8%; TTM Jun-2026 operating margin ≈20.9% [S13]
  • Net cash: Cash KRW 26.45 bn + short-term instruments KRW 26.50 bn vs KRW 20 bn CB (end-2025) [S13], [S6]
  • Committed parent: Samoh invested KRW 5 bn in the 2025 CB and provides cGMP manufacturing [S6], [S7]
  • Broad catalogue: 142 products across six families [S4]

Weaknesses

  • Extreme related-party concentration: 77.27% of FY2025 revenue to Samoh; ~96% of amino acid sales [S6]
  • No owned manufacturing: Production fully outsourced [S7]
  • Volatile earnings history: Operating losses in FY2019 and FY2024; revenue fell 23.6% and 19.6% in FY2023–FY2024 [S11]
  • Value-destructive related-party acquisition: KRW 19.0 bn API rights (2015) written down to KRW 1.96 bn by end-2025 [S6]
  • Shrinking API segment: API revenue KRW 5.3 bn (FY2024) to KRW 4.3 bn (FY2025) [S6]
  • Low visible R&D spend: SG&A R&D KRW 0.14 bn in FY2025 [S13]
  • Weak disclosure and governance optics: Co-CEOs are parent's co-CEOs; four Oh family directors [S7]; no IR materials or guidance

Opportunities

  • GLP-1 manufacturing localisation in Korea: Press reports of Eli Lilly reviewing Korean GLP-1 production [S7]
  • Peptide CDMO demand boom: Bachem guiding 35–45% 2026 growth [S21]
  • Direct export expansion: Company sells via direct export as well as through Samoh [S6]; CPhI marketing [S8]
  • Customer-requested new developments: Global customers request new products [S20]
  • Import substitution in Korea: Korea relies mostly on imported amino acids [S20]; ≈KRW 50 bn/yr unnatural amino acid imports (dated) [S26]
  • ESG-qualified supplier status: EcoVadis and ISO certifications in progress [S8]

Threats

  • Dilution overhang: KRW 20 bn CB convertible at KRW 957 since 30 Jun 2026 (≈20.9 m shares, ≈23.8% of prior share base) [S7]
  • New well-capitalised domestic competitor: Daesang's ≈KRW 50.2 bn AMINO GmbH acquisition, plant at ~105% utilisation [S23]
  • Other Korean entrants: Daebong LS pursuing FDA-grade pharma amino acids and GLP-1 supply [S28]
  • Parent's commercial fortunes: Samoh's sales effectively determine Aminologics' results [S6]
  • Further intangible impairment: API rights impaired in both FY2024 and FY2025 [S6]
  • Speculative share-price volatility: 5-session ~84% surge and KRX warning notice in Jan 2026, followed by full reversal [S7], [S13]

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
15 May 2025Q1 2025 quarterly report filed [S11]Start of recovery year
Jun 2025KRW 20 bn 4th private CB issued; Samoh subscribed KRW 5 bn; conversion price KRW 957 [S6], [S7]Funded liquidity; created ~20.9 m-share overhang
14 Aug 2025H1 2025 report filed [S11], [S13]TTM revenue still only KRW 15.9 bn at mid-year
14 Nov 2025Q3 2025 report filed: 9M revenue KRW 15.5 bn (amino acids 77%) [S7], [S11]Confirmed amino acid-led recovery
26 Dec 2025Share price closes at KRW 915 [S7]Pre-rally base
30 Dec 2025Share price jumps to KRW 1,194 [S7]Start of GLP-1-themed rally
2 Jan 2026Shares rise 20% to KRW 1,438 [S7]Momentum on GLP-1 theme
5 Jan 2026KRX designates investment warning advance notice; intraday 52-week high KRW 1,825; close KRW 1,681 [S7]Regulatory cooling measure after ~84% five-session gain
6 Jan 2026Intraday high KRW 1,940 (52-week high); close KRW 1,682; market cap ≈KRW 147.7 bn [S7]Peak valuation; Samoh's stake valued ≈KRW 45.8 bn
12 Mar 2026Notice of 29th AGM with e-voting via Samsung Securities [S5]Governance
23 Mar 2026FY2025 business report filed [S14], [S6]Revenue KRW 22.0 bn, OP KRW 3.6 bn, NI KRW 3.5 bn
31 Mar 202629th AGM results; FY2025 settlement notice [S14], [S5]Governance
29 Apr 2026IB Tomato analysis highlights record dependence on Samoh and API-rights impairments [S6]Raised governance/quality-of-earnings concerns
15 May 2026Q1 2026 report: revenue KRW 5.4 bn (+13.9%), OP KRW 0.6 bn [S11]Slow start to 2026
30 Jun 20264th CB conversion window opens [S7]Dilution overhang becomes live
10 Jul 2026Large shareholding status report filed [S14]–
13 Jul 2026Large shareholding status report and officer/major-shareholder ownership report filed [S14]–
14 Aug 2026H1 2026 report: Q2 revenue KRW 8.2 bn (+73.1%), OP KRW 2.0 bn; amino acids 87% of Q2 revenue [S11], [S12]Best quarter since 2022
15 Oct 2026Share closes at KRW 977, near the bottom of its 52-week range [S13], [S17]Rally fully reversed
Dec 2025 – Mar 2026Daesang announced (Dec 2025) and completed (Mar 2026) acquisition of 100% of German specialty amino acid producer AMINO GmbH for ≈KRW 50.2 bn [S23]A large Korean food-chemicals group entering high-purity/pharma amino acids — a new domestic competitor with plant capacity
12 Mar 2026Bachem FY2025: sales CHF 695.1 m (+14.8%); 2026 guidance 35–45% growth in local currency [S21]Confirms strong peptide/GLP-1 demand for upstream materials
Jul 2026Daebong LS selected for a global GMP support programme (≈KRW 0.4 bn) to prepare pharma amino acids for US FDA, partnering with CJ CheilJedang on four essential amino acids [S28]Another Korean listed company moving toward pharma-grade amino acids
Aug 2026AMINO GmbH reported ~105% plant utilisation with Q2 revenue of KRW 26.5 bn within Daesang [S23]Scale gap: one competitor's quarterly revenue exceeds Aminologics' annual revenue

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment: Total revenue fell from KRW 22,800 Mn in FY2021 to KRW 22,000 Mn in FY2025.
Aminologics Co., Ltd. — Revenue by Segment
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Total revenue22,80027,30020,90016,80022,000
Amino Acid revenue8,500——11,50017,700
API revenue14,300——5,3004,300

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Aminologics website, company overview & history— Founding date, former name, co-CEOs, address, business scope, history 1997–2014 (aminologics.co.kr)
  2. S2Aminologics website, CEO message— Strategy themes; co-CEO names (aminologics.co.kr)
  3. S3Aminologics website, R&D centre— R&D centre date/location; head; ARCA description (aminologics.co.kr)
  4. S4Aminologics website, products— Product families; 142 products; featured CAS numbers and purities (aminologics.co.kr)
  5. S5Aminologics website, homepage— AGM/settlement notices; family sites; ARCA sub-systems; legacy DVR metadata (aminologics.co.kr)
  6. S6IB Tomato / NewsTomato, "Aminologics, growth relying on largest shareholder" (paywall 29 Apr 2026; public 4 May 2026)— FY2025 results; segment revenue FY2024–25; Samoh sales FY2023–25; CB; API-rights price and impairments (newstomato.com)
  7. S7Dailypharm, 7 Jan 2026— Share-price surge; KRX notice; GLP-1 theme; shareholders; board; CB conversion price/timing; Osong cGMP outsourcing (dailypharm.com)
  8. S8Dailypharm, 26 Feb 2024— Amino acid growth since 2020; >KRW 15 bn in 2023; CPhI; EcoVadis/ISO (m.dailypharm.com)
  9. S9Asia Economy via Daum, 9 Jun 2022— Q1 2022 results and segment split; 2021 mix; business history since 2009; Jan 2017 outsourcing (v.daum.net)
  10. S10NewsTomato interview, 13 Aug 2012— ARCA positioning; legacy IT/energy wind-down; Kim Won-seop background (newstomato.com)
  11. S11etfshopping.com, 074430 financials and earnings · 10-year revenue and OP; growth; debt ratio; cash change; quarterly results; filing dates
  12. S12butler.works, Aminologics— FY2021–25 revenue/OP/NI; Q2 2026 segment mix; filings list (butler.works)
  13. S13valueline.co.kr, Aminologics income statement / balance sheet (accessed 15 Oct 2026) · FY2025 and TTM P&L detail; balance sheet; share counts; quarter-end prices; latest close
  14. S14financialfilings.com, Aminologics— English business summary; filings list and dates (financialfilings.com)
  15. S15Simply Wall St, company information · Listing date; shares; employees (40); CEO J.S. Oh
  16. S16Investing.com, company profile— Director names and ages (m.uk.investing.com)
  17. S17StockHub, 074430— 52-week range; market cap; zero analyst reports (stockhub.kr)
  18. S18CPHI Online product listings— Catalogue items; on CPHI since 2015 (cphi-online.com)
  19. S19Justia Trademarks— Trademark filing 29 Dec 2010 (trademark.justia.com)
  20. S20valueline.co.kr, 26.1Q company summary— Business description; six APIs and therapeutic areas; market structure statement (valueline.co.kr)
  21. S21Bachem FY2025 media release (12 Mar 2026)— Peer financials; 2026 guidance (bachem.com)
  22. S22butler.works, Daebong LS— Peer FY2025 financials; multiples (butler.works)
  23. S23E-Daily, 18 Aug 2026— Daesang/AMINO GmbH acquisition, utilisation, Q2 revenue (en.edaily.co.kr)
  24. S24GII Korea / 360iResearch amino acid market report— Market size and CAGR; tariff note (giikorea.co.kr)
  25. S25GII Korea / Technavio amino acid market report— Market growth estimate (giikorea.co.kr)
  26. S26KIDD news, unnatural amino acid production technology— Transaminase route; market estimates (undated) (kidd.co.kr)
  27. S27Stock Events, 074430.KQ— Historical dividend entries (stockevents.app)
  28. S28MTN, 1 Jul 2026— Daebong LS global GMP programme and CJ partnership (news.mtn.co.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.